• Home
  • Method Development/Transfer And Validation Lab CRO Services

Method Development, Validation And Transfer: One Lab For The Whole Method Lifecycle

Develop, validate or transfer is a fork you want to take once. Tell us what exists today, and you get the cheapest defensible path back in writing.

De-Risk Your Method, Development to GLP Validation.

Brief PhDs on your analyte, matrix and stage.
  • You Have A Molecule And No Method: Development Builds One, From A 500+ Library
  • Your Data Will Face FDA: Validation Proves The Method Against Its Stated Criteria
  • Your Validated Method Must Change Labs: Transfer Moves It With Its History Intact
  • One Lifecycle, One Lab: 90%+ Of Methods Built Here Stay To Run Study Samples Here

Regulated And Inspected By:

  • Good Laboratory Practice for Nonclinical Laboratory Studies | NorthEast BioLab
  • Food and Drug Administration (FDA | NorthEast BioLab
  • College Of American Pathologists | NorthEast BioLab
  • International Orgaization for Standardization | NorthEast BioLab

The PhD Scientists Behind Your Method Lifecycle

20+ Years In Bioanalysis
700+ Sponsor Studies
500+ Custom Assays
200+ Investigational Drugs

Three Conversations, One Lab: Build It, Prove It, Move It

Every method engagement starts as a build, a proof or a move. Your starting point gets named quickly, because the lifecycle costs less when one group carries it.

The First Door: A Molecule With No Method Yet

  • Method development builds it: chemistry chosen deliberately and documented to be graded
  • Feasibility read in days, typical small molecule builds complete in two to four weeks

The Lifecycle Argument: Build Once, Keep It

  • Methods built here validate cleanly because they were built to the grading criteria
  • More than 90% then stay for validation and study samples, which is the whole point

The Second Door: Data That Must Survive FDA

  • Method validation proves it: the full parameter set against criteria stated up front
  • Fit-for-purpose, GLP and GCLP tiers matched to what the data will have to defend

Changes Are Scoped Steps Here, Never Restarts

  • New matrix, new species or a new range revalidates only the parameters that moved
  • The method file keeps one continuous history through every change your program makes

The Third Door: A Validated Method On The Move

  • Method transfer moves it: replication proven on like-for-like instruments, in or out
  • Bridging keeps pre-move and post-move results one dataset your submission can cite

Documented To Stay, And Documented To Leave

  • Every stage writes files any qualified lab could run, so nothing holds you hostage
  • Sponsors stay for the work: two thirds returning, one in three past a third year

Where Your Method Stands Today Decides The First Step

An assay that does not exist yet, a method that needs proving and one living elsewhere each start differently. The wrong first step costs a fiscal quarter.

  1. A Molecule And No Method

    Development builds it around your molecule and matrix from first principles

    Method Development
  2. A Method That Needs Proving

    Validation grades it to the tier your data faces, fit-for-purpose through GLP

    Method Validation
  3. A Method Living Elsewhere

    Transfer moves it here with replication and bridging, history intact

    Method Transfer
  4. A Validated Method That Changed

    Matrix, species or range moved; partial validation covers only what moved

    Method Validation
  5. A Study Waiting On Samples

    Regulated sample analysis picks up the proven method and runs batches to your calendar

    Bioanalytical CRO
  6. A Discovery Pace Question

    The research tier runs lean and fit-for-purpose until your program earns an IND

    Non-GLP Testing

Ready To Start? Scope Your Method Programme.

Tailored method quote in 2 days.

Three Routes, One Building: The Lifecycle Is The Reason To Start Now

The wrong lane costs a re-validation. We assess the method, data and reagents you have before recommending where to begin.

Talk Science First? Book a Call With Our Method Experts.

Discuss stage, matrix and validation tier.
  • The wrong door costs a fiscal quarter: buying validation for a method that needed rebuilding, or rebuilding one that only needed a partial. The first call names the right door in writing.
  • More than 90% of methods developed here go on to run study samples here, so every build, validation and transfer is done with the next two years of your program in mind, not the invoice.
  • All three doors open onto the same benches: twelve LC-MS systems, the full immunoassay fleet and senior scientists carrying 18+ years in the industry, with five FDA inspections behind the files.

500+Custom Methods Carried Through This Lifecycle In House

90%+Of Methods Developed Here Stay For Study Sample Analysis

What Does The Lifecycle Cost?

Nothing is sold as a bundle: each stage is quoted alone with its tier named, and the first call establishes which stage you are in before any money moves. Development, validation and transfer each carry their own clocks, stated on their own pages, and a senior scientist replies within two business days.

Your Cost Cannot Move Mid-Study

The quote you approve is the price you pay, at every stage. Cost cannot move without an SOW addendum you have already approved, which is what makes a multi-year method lifecycle a thing a small biotech can actually budget.

Sponsors Across The Lifecycle, Quoted Directly

Two thirds of the 100+ sponsors we work with each year return, and one in three is past a third year with us.

  • VP, Head of Clinical Operations

    Our projects with NorthEast BioLab include successful method development, validation, stability studies during Clinical Phase I – IV studies.

  • VP, PK PD Analysis

    NorthEast BioLab always exceeds expectations on bioanalytical assay development, validation, and sample analysis.

  • Sr. Associate Dir., Clinical Trials

    We have worked with NorthEast BioLab for over ten years given their commitment to highest quality bioanalytical data.

  • Executive Director, Drug Research

    NorthEast BioLab provides critical insight, and are compliant with regulatory standards and industry best practices. We highly recommend them and look forward to working together again.

  • VP, Bioanalytical Development

    NorthEast BioLab is the most responsive and thorough bioanalysis lab services CRO.

  • Head, Bioanalytical Development

    NorthEast BioLab goes the extra mile. We look forward to more meaningful collaborations.

Develop, Validate or Transfer? Tell Us Your Stage.

Share the analyte and matrix. We'll scope the path.

Why The Lifecycle Beats The Errand

A method bought as an errand dies with its vendor. A method carried through its lifecycle in our building keeps its history, its documentation and its momentum.

What You Receive

  • The right door named in writing after the first call, with the reasoning attached
  • A method with one continuous, audited history from first build to final transfer
  • Documentation at every stage written so QA teams and inspectors can follow it later
  • One lab from research tier to FDA-facing work, so growth never has to mean moving out

What We Need From You

  • Where the method stands today: nothing yet, a draft, validated, or already moving
  • The molecule and matrix, since every door starts from the same two questions anyway
  • Your regulatory context, because it decides which tier the work has to run under
  • The date that matters most, so the plan is built backwards from your own milestone
Basics Of Bioanalysis | NorthEast BioLab

The Basics of Bioanalysis: How Do We Develop and Validate Your Bioanalytical Method?

Bioanalysis is an essential tool in drug discovery and development for determining the concentration of drugs and their metabolites in biological matrices….

One Method, Five Years: A Representative Lifecycle, Step By Step

Built, validated, run, revalidated and finally transferred out, the assay stays with one team and every record sits in a single file.

  1. 1. Molecule Arrives

    A biotech sends the structure, the matrix and the study behind them

  2. 2. Method Built

    Development locks the chemistry and documents the reasoning

  3. 3. Method Proven

    Full validation to FDA guidance under GLP, report audited

  4. 4. Studies Run

    Preclinical then clinical batches, cohort by cohort, for years

  5. 5. Change Absorbed

    A matrix change triggers partial validation, history intact

  6. 6. Second Site Added

    Cross-validation proves both labs read the same truth

Why Do Sponsors Keep Every Stage Of A Method With One Team?

Because the recommendation is written against your regulatory context, and the same team runs all three lanes, so nobody oversells one.

Get Your Method Plan Reviewed By PhD Scientists.

Send your plan. We'll flag pitfalls before they cost you.
  • One lab for the whole method lifecycle: built, proven, run, changed and moved here
  • Five FDA inspections and GLP and GCLP practice behind every stage of the lifecycle
  • 500+ custom methods built and more than 90% carried forward into study sample analysis
  • Methods documented to travel, so staying here is a choice sponsors keep remaking

Regulated And Inspected By:

  • Good Laboratory Practice for Nonclinical Laboratory Studies | NorthEast BioLab
  • Food and Drug Administration (FDA | NorthEast BioLab
  • College Of American Pathologists | NorthEast BioLab
  • Clinical Laboratory Improvement Amendments | NorthEast BioLab
  • International Orgaization for Standardization | NorthEast BioLab
  • United States Drug Enforcement Administration | NorthEast BioLab

Describe Your Starting Point, And Get A Recommendation In Writing

No method yet, a draft, a validated method or one on the move: name the state, and a senior scientist writes up the route on the platforms linked below.

Related FAQs

What outsourcing leads ask at the develop-validate-transfer fork, answered.

Development first, or validation first?

Is our situation a transfer or a redevelopment?

What does fit-for-purpose mean against full validation?

Do we have to buy the whole lifecycle?

Our method was validated years ago at another lab. Is it still good?

Who owns the method at each stage?

How fast can the whole path run, end to end?

Explore More Solutions

Whichever of the three you choose, the method finishes on the systems that will run your study samples.